StarZero All shows Try the podcast clipper →

Malinka Walaliyadde

Co-Founder & CEO, AKASA · 6 appearances on the record.

computed by AI from the episodes · how this works → · full disclaimer →

founderexecutiveinvestor@MalinkaWal ↗LinkedIn ↗akasa.com ↗

Malinka Walaliyadde is the co-founder and CEO of AKASA, an AI platform automating revenue cycle management and administrative operations for health systems. Previously, he was a deal partner at Andreessen Horowitz, where he helped build the bio and healthcare investment team and sourced investments such as Benchling.

12statements → 9claims → 5claims resolved → 60%fully supported → 3.92/5average certainty → 2.08/5average debate potential →

3 supported 2 partly supported 0 contradicted 4 not checkable as stated how the 9 claims stand · each chip opens the sources

2 predictions · 7 assertions · 1 opinion · 2 insights · every statement was checked. The predictions and assertions are the 9 claims: statements the public record can support or contradict. 5 are resolved, and 4 name no date, number or outcome precise enough to check. Everything else (opinions, insights, what ifs, disclosures) can never be settled by the record, so it carries no assessment.

The record, in short

What the tape says about how Malinka argues and how the claims held up. Everything they said, and everything said about them, is in the tabs below.

Their most notable supported claim

Assertion Supported
Walaliade: Hospitals are increasingly taking financial risk for patient care
“Hospitals are increasingly taking financial risk on their patients. They are financially on the hook for excessive care.”
Malinka Walaliyadde Jan 2, 2019 ▶ 12:53 a16z Podcast | Taking the Pulse on Bio

Expressed certainty vs assessment result

none yet certainty 1
none yet certainty 2
none yet certainty 3
75% certainty 4
100% certainty 5

weighted support: a fully supported claim counts one, a partly supported claim counts half. Each filled bar is clickable and opens exactly those claims; "none yet" means nothing said at that certainty level has resolved yet

How they sound: speaking style how? →

282 words/min while actually speaking · 11.2 um and uh per 1k words

No argument clarity score for Malinka Walaliyadde: no usable question→answer exchanges on raw tape (a fair score needs 8+). We do not score a sample that small. Roundtable and news formats yield far fewer direct exchanges than interviews.

Measured by listening to the audio itself: 3,577 words across 5 episodes of raw-level tape, transcribed verbatim with every um and uh kept, each one attributed only where the alignment onto our timed stream is unambiguous. These are measurements of speaking style. We do not rank them: across this corpus, fluency and argument quality are nearly uncorrelated (ρ≈0.2), and smooth talking does not signal clear thinking. How it's measured →

Everything Malinka Walaliyadde said on the a16z Podcast that made the record, most notable first. Filter by type, assessment or year in the ledger →

Assertion Partly supported
Walaliade: AI models outperform human physicians in top 2017 medical journals
“Two years ago, there weren't that many examples of prominent journals publishing AI and healthcare pieces where it was, you know, shown to work in healthcare context, and now it feels like every month there's a new nature paper or something coming out where, y…”
Malinka Walaliyadde Jan 2, 2019 ▶ 1:52 a16z Podcast | Taking the Pulse on Bio
Assertion Not checkable as stated
Walaliate: Genomics has few true healthcare applications 20 years after HGP
“We certainly haven't lived up to that, and in fact, it's been a little difficult to see exactly where genomics has had a true application today.”
Malinka Walaliyadde Jan 2, 2019 ▶ 1:19 a16z Podcast | When Will Genomics Live Up to the Hype?
Prediction Not checkable as stated
Walaliyadde: The magical continuous diagnostic machine of the future is your bathroom
“I actually think the magical diagnostic machine of the future is your bathroom.”
Malinka Walaliyadde Jan 2, 2019 ▶ 18:28 a16z Podcast | On the Genomics of Disease, From Science to Business
Assertion Partly supported
Walaliyadde: Assurex generated $60M in revenue despite only 20% test reimbursement
“There's a company called Assurex in mental health. They were making sixty million dollars in revenue last year, but they were only getting 20% of their tests reimbursed.”
Malinka Walaliyadde Jan 2, 2019 ▶ 24:40 a16z Podcast | On the Genomics of Disease, From Science to Business
Assertion Supported
Walaliade: Hospitals are increasingly taking financial risk for patient care
“Hospitals are increasingly taking financial risk on their patients. They are financially on the hook for excessive care.”
Malinka Walaliyadde Jan 2, 2019 ▶ 12:53 a16z Podcast | Taking the Pulse on Bio
Insight
Walaliade: Health plans demand cost-saving proof over product engagement
“Health insurance plans care a lot more about saving money than offering an engaging product and so for an early-stage startup, it's a lot harder for them to do the saving money piece, because that takes a long study to prove, and they do it eventually, but it'…”
Malinka Walaliyadde Jan 2, 2019 ▶ 18:59 a16z Podcast | Taking the Pulse on Bio
Assertion Supported
Walaliyadde: One dominant company drove a decade of sequencing cost drops
“The dominant player in the sequencing machine space has almost entirely by itself been driving down the cost of sequencing over the last decade or so.”
Malinka Walaliyadde Jan 2, 2019 ▶ 4:15 a16z Podcast | On the Genomics of Disease, From Science to Business
Assertion Not checkable as stated
Walaliyadde: Medicine lacks effective methods for early cancer detection and active diagnosis
“Risk tests just tell you your chance of getting cancer. They don't actually tell you if you have cancer right now, and so if you're at higher risk, that probably means you want to get tested more frequently, but we don't have good methods of testing and diagno…”
Malinka Walaliyadde Jan 2, 2019 ▶ 14:16 a16z Podcast | On the Genomics of Disease, From Science to Business
Prediction Not checkable as stated
Walaliyadde: Single-payer systems like the UK will drive higher genomic test adoption
“In fact, I think in single-payer systems like the UK or outside, we might see much more adoption of some of these genomic tests.”
Malinka Walaliyadde Jan 2, 2019 ▶ 24:28 a16z Podcast | On the Genomics of Disease, From Science to Business
Opinion
Walaliyadde: Non-invasive prenatal testing was the first genetic application and is saturated
“Non-invasive prenatal testing and infertility is one major area. In fact, that was the first. It was the first to make it big in genetics, and it's gotten a little saturated.”
Malinka Walaliyadde Jan 2, 2019 ▶ 27:36 a16z Podcast | On the Genomics of Disease, From Science to Business
Insight
Walaliyadde: Genomics splits into sequencing hardware like Intel and clinical applications
“And an easy way to think about genomics is there's a sequencing layer, which is the companies that make the sequencing machines like Illumina, which is like sort of Intel and chips. And then there's the application layer, which are companies that are using thi…”
Malinka Walaliyadde Jan 2, 2019 ▶ 4:25 a16z Podcast | On the Genomics of Disease, From Science to Business
Assertion Supported
Walaliyadde: Illumina expanded into the applications layer via Verinata, Grail, and Helix
“Lumina has started realizing that as well and is itself building applications. They bought a company called Verinata, which is a NIPT company... You know, they have a cancer company called Grail... There's a company called Helix. So they have started participa…”
Malinka Walaliyadde Jan 2, 2019 ▶ 21:42 a16z Podcast | On the Genomics of Disease, From Science to Business

Appearances (6)

EpisodeDateSpeaking time
a16z Podcast | Taking the Pulse on Bio Jan 2, 2019 4m
a16z Podcast | The Taxonomy of Collective Knowledge Jan 2, 2019 2m
a16z Podcast | The Rise of the Digital 'Pill' Jan 2, 2019 2m
a16z Podcast | When Will Genomics Live Up to the Hype? Jan 2, 2019 3m
a16z Podcast | Produce or Perish! (What We Eat) Jan 2, 2019 1m
a16z Podcast | On the Genomics of Disease, From Science to Business Jan 2, 2019 5m
Made with StarZero

Turn any episode into a week of clips.

This entire site, over 1,000 episodes transcribed, diarized, checked and made playable, runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the moments worth sharing, cuts them, captions them, and reframes them for every feed.

Try the podcast clipper Learn more